|Last: || $4.010|
|Volume: || 247,400|
As Of: 2013-05-24 20:30:42 ET
*Quotes delayed by 20min.
Rosetta Genomics Ltd (NASDAQ:ROSG)
Rosetta Genomics Ltd. develops and commercializes a range of microRNA-based diagnostic tools. MicroRNAs are a group of genes that are produced using instructions encoded in DNA. The company offers diagnostic tests, including miRview mets for identification of the primary site of metastatic cancer; miRview mets2, a microarray-based test to identify 42 tumor types that include carcinomas, soft tissue tumors, lymphoma, and other malignancies; miRview squamous to differentiate squamous from non-squamous non-small cell lung cancer; miRview meso to differentiate mesothelioma to differentiate mesothelioma, a cancer connected to asbestos exposure and other risk factors, from other carcinomas in the lung and pleura; and miRview lung, a lung cancer classification test for cytology samples. It also has various tests under development consisting of miRview kidney for differentiating four histological types of renal or kidney tumors, as well as body fluid based diagnostic tests for heart failure, a clinical syndrome resulting from structural or functional cardiac disorder. The company distributes its products primarily in Australia, Canada, Greece, India, Israel, New Zealand, Qatar, Saudi Arabia, Singapore, Turkey, and the United Arab Emirates. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.